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Abstract
Background: Interleukin-18 is a pro-inflammatory cytokine suspected to be associated with
atherosclerosis and its complications. We had previously shown that one single nucleotide
polymorphism (SNP) of the IL18 gene was associated with cardiovascular disease (CVD) through
an interaction with smoking. As a further step for elucidating the contribution of the IL-18 pathway
to the etiology of CVD, we here investigated the association between the genetic variability of two
IL-18 receptor genes, IL18R1 and IL18RAP, with the risk of developing CVD.
Methods:  Eleven tagging SNPs, 5 in IL18R1  and 6 in IL18RAP, characterizing the haplotypic
variability of the corresponding genes; were genotyped in 5 European prospective CVD cohorts
including 1416 cases and 1772 non-cases, as part of the MORGAM project. Both single-locus and
haplotypes analyses were carried out to investigate the association of these SNPs with CVD.
Results: We did not find any significant differences in allele, genotype and haplotype frequencies
between cases and non-cases for either of the two genes. Moreover, the search for interactions
between SNPs located in different genes, including 5 IL18 SNPs previously studied in the MORGAM
project, and between SNPs and environmental factors remained unfruitful.
Conclusion: Our analysis suggests that the variability of IL18R1 and IL18RAP genes are unlikely to
contribute to modulate the risk of CVD.
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Background
Interleukin-18 (IL-18) is a pro-inflammatory molecule
that has been shown to be involved in the susceptibility of
several human complex diseases such as immune dis-
eases, type I diabetes and cardiovascular diseases (CVD)
[1]. The hypothesized mechanism by which IL-18 may be
linked to CVD risk is related to atherosclerosis and its
complication [2-9]. Consistent with this hypothesis, high-
est IL-18 levels were shown to be associated with
increased carotid intima-media thickness [10] and with
cardiovascular mortality in a cohort of patients with coro-
nary artery disease [7,8]. As initiating the IL-18 signalling
cascade requires the formation of a heterodimeric recep-
tor (IL-18R) composed of a binding chain α, termed IL-
18R1 or IL-18Rα, and a signal transducing β chain, termed
IL-18RAP (for IL-18 receptor accessory protein) or IL-
18Rβ [11-13], both IL-18R1 and IL-18RAP might also be
good candidates for CVD. IL-18R1 and IL18-RAP are
expressed on a variety of cells including macrophages, T
lymphocytes, and natural killer cells, which are ascribed a
key role in atherosclerotic plaque rupture [14,15]. The
hypothesized relationship between IL-18 receptors and
CVD could be reinforced by showing that single nucle-
otide polymorphisms (SNPs) within the IL-18R1  and
IL18-RAP genes could be associated with CVD.
While IL18R1  and IL18RAP  polymorphisms have been
found associated with diseases such as schizophrenia,
HSV1 seropositivity and atopic asthma [16,17], little is
known about their contribution to CVD. IL18R1  and
IL18RAP tag SNPs have been investigated in a German
cohort of coronary artery disease patients in relation to
cardiovascular mortality [9] but no association was
observed. However, the number of patients experiencing
the end point of interest was moderate (n = 142) and
could have limited the power to detect mild genetic
effects.
Therefore, in order to get a better insight of the contribu-
tion of IL18R1 and IL18RAP genes on CVD risk, we inves-
tigated the association of tagging SNPs within these genes
with the risk of CVD in the MORGAM Project [18], a col-
laborative study pooling several European (Finns, Swed-
ish, Northern Irish and French) prospective population
cohorts expected to provide ample power to detect mod-
erate genetic effects. In addition, in light of our recent
finding suggesting that smoking could modulate the effect
of IL18 SNPs on the risk of CVD [19], we were interested
in testing whether IL18R1 and IL18RAP SNPs could also
interact with smoking, an hypothesis that has never been
investigated before.
Methods
MORGAM study populations
MORGAM is a multinational collaborative project of sev-
eral European population cohorts, which were followed
up for cardiovascular disease and whose descriptions have
already been published [18]. The present report was based
on the analysis of five cohorts, two from Finland (FIN-
RISK, ATBC), one from France and one from Northern Ire-
land, (both issued from the PRIME Study), and one from
Sweden. The FINRISK cohort comprised two surveys with
baseline investigations five years apart (1992 and 1997).
Both were pooled in this report after having checked for
consistency across surveys and the analysis was adjusted
for survey. All individuals were followed up over a median
period of 6.0 (maximum 10.9) years for mortality and for
several cardiovascular outcomes including thromboem-
bolic, coronary heart disease (CHD) and stroke events. To
facilitate the study of multiple endpoints and to reduce
genotyping costs, a case-cohort design [20,21] has been
adopted in MORGAM. In each population cohort, a sub-
set of individuals from the whole cohort was randomly
selected independently of disease status to be part of a
subcohort according to population-specific sampling
probabilities. These probabilities were dependent on sex
and age such that older subjects had a higher selection
probability and that age distributions were similar in cases
and in the subcohort. All individuals were followed up for
clinical outcome that was obtained mostly from national
death register, MONICA and hospital discharge registers,
and regional health information system [18]. Genotyping
was however restricted to all subcohort members and to
all additional subjects who were not part of the subco-
horts but who experienced cardiovascular outcomes dur-
ing the follow-up. Subjects with cardiovascular events
prior to the baseline examination were excluded from the
analysis.
Globally, the subcohort was composed of 2016 subjects.
In this study, we were interested in stroke events (ischemic
and hemorrhagic) and CHD events (including definite
and possible acute myocardial infarction, coronary death,
unstable angina pectoris and cardiac revascularization).
Both ischaemic and hemorrhagic stroke were included in
the analysis because there is often insufficient data to sep-
arate between the subtypes in this population-based
study. About 80% of the strokes are ischaemic in these
populations. Detailed events definition is available in the
cohort descriptions [22]. Both fatal and non-fatal events
were considered and, when multiple events occurred dur-
ing the following-up, only the first one was studied. The
case-cohort data set was composed of 1416 cases (244
subjects in the subcohort and 1172 subjects from outside
the subcohort) and 1772 non-cases.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Quality control of the extracted DNA
A central core laboratory aliquotted the DNA samples
from all cohorts except the two cohorts of the prospective
study PRIME. Fluorescent label PicoGreen (Invitrogen,
Carlsbad, CA, USA) was used to normalize the DNA con-
centration prior to aliquotting. The samples were geno-
typed with quality control marker panel including sex-
specific markers (one marker in the Y-chromosome, 2 in
X-chromosome and 3 autosomal markers). Genotype-
inferred gender was compared with the clinical records.
The presence of discrepancies may indicate either that
sample labels have been mixed or contamination with
another DNA. This can be observed only when a sample
of men has been mixed or swapped with a sample of
women. Therefore, genotyped samples also included ~2%
known duplicates, 5% blinded duplicates and negative
controls. We then excluded all discrepant samples. The
genotyping success rate was at least 98% for all control
markers and we observed less than 0.25% genotyping
errors based on the duplicate comparison. This quality
control process was performed only once and independ-
ently of any planned SNP-specific genotyping.
Genotyping
SNPs genotyped in the present study were exactly those
that were previously studied in the AtheroGene cohort [9]
where detailed description of the selection criteria can be
found. Briefly, these were haplotype tagging SNPs selected
to capture more than 95% of the haplotype diversity of
the regulatory, coding and flanking intronic regions of the
IL18R1 and IL18RAP genes according to the information
available in the Innate Immunity Programs for Genomic
Applications database http://innateimmunity.net/. These
included 5 SNPs in IL18R1, rs1420098 (T-6/in1C),
rs1420096 (T-17/in8C), rs11465656 (+43Ins/Del),
rs3732127 (G+404C), rs11465660 (C+968A), and 6
SNPs in IL18RAP, rs11465670 (T-1301C), rs4851581 (A-
992G), rs1420106 (G-697A), rs1420105 (C-622T),
rs11465673 (T-366C), rs11465702 (A+55/inG). In addi-
tion to these 11 SNPs, 5 IL18 SNPs previously studied in
the MORGAM project [19] were also investigated in the
search for interaction among SNPs of the IL-18 pathway.
These were rs1946519 (G-887T), rs360717 (C-105T),
rs549908 (S35S (A/C)), rs5744292 (A+183G) and
rs4937100 (T+533C). Genotyping was performed using
the TaqMan 5' nuclease detection assay on a 7000
Sequence Detection System (Applied Biosystems). All
information for genotyping (PCR primers, probes, condi-
tions of amplification and hybridization) can be found on
the GeneCanvas website http://genecanvas.ecgene.net.
Statistical analysis
Deviation from Hardy-Weinberg equilibrium (HWE) was
tested by a standard χ2 with 1 degree of freedom and allele
frequencies were estimated using the gene-counting
method in each subcohort separately. Association of
IL18R1 and IL18RAP SNPs with the case/non-case status
was tested using a logistic regression model including the
inverse of the sampling probability as an offset [21]. In
most analyses, additive allele effects were assumed except
for rare alleles where dominant models were considered.
In order to deal with linkage disequilibrium (LD) between
SNPs of the same gene, haplotype analyses were further
carried out using the THESIAS software [23]. Tests of asso-
ciation between haplotypes and the case/non-case status
were performed using the likelihood ratio test.
Analyses were performed separately in each population
and were adjusted for age at baseline, baseline status, gen-
der and smoking status when appropriate. Homogeneity
of the associations across cohorts was assessed by use of
the Mantel-Haenszel statistics [24,25] that was subse-
quently used for estimating pool odds ratio (OR) in the
whole study. The Mantel-Haenszel method is a standard
way to estimate averaged OR by weighting each log(OR)
obtained in a given population by the inverse of their var-
iance.
For each gene, adjustment for multiple testing was made
by applying a Bonferroni correction for the number of
inferred haplotypes times the number of population
cohorts.
The DICE method [26,27] was used to investigate SNP ×
SNP interactions as well as interaction of SNPs with cov-
ariates including age, gender, smoking status and body
mass index. DICE is an algorithm that explores in an auto-
mated way all combinations of one, two or three covari-
ates, that could be SNP or environmental factors, acting
either additively or in an interactive way. The selection for
the most parsimonious model of interaction, if any, is
based on a Information Criterion. This search was first car-
ried out separately in each cohort and then in the com-
bined sample while adjusting for cohorts.
Results
A brief description of the five populations used for this
analysis is given in Table 1, with a total number of 1772
non-cases and 1416 cases of CVD. Three cohorts, ATBC,
PRIME/France and PRIME/N.Ireland included men only.
Among the 1,416 cases, 923 experienced only a CHD
event, 425 only a stroke event and 68 experienced both
events. The first event was fatal for 258 CHD cases and 55
stroke cases.
All analyses were performed separately in each cohort but,
for ease of presentation, most of the results presented are
those obtained in the whole study, after having checked
the homogeneity of the associations.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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IL18R1 gene
In each MORGAM subcohort, all genotype distributions
were compatible with Hardy Weinberg equilibrium
(HWE). For three SNPs, allele frequencies differed across
subcohorts (Additional File 1). The SNP showing the
strongest difference (p < 0.0001) across subcohorts was
the rs11465660, the frequency of the rs11465660-A allele
varying from 0.07 in France to 0.15 in Sweden. None of
the IL18R1 SNPs was consistently associated with CVD
(Table 2 – Figure 1). The rs3732127-C allele was slightly
more frequent in Sweden cases than in Sweden non-cases
(0.22 vs 0.14), but this association (p = 0.037), not found
in others cohorts, was no longer significant after correc-
tion for multiple testing
LD pattern between IL18R1 SNP is shown in Figure 2.
Eight haplotypes with frequency greater than 0.02 in at
least one subcohort were inferred from the 5 IL18R1 tag
SNPs (Table 3). The haplotypic structures were broadly
homogenous across the five cohorts. The rs11465656-Del
allele was the only allele carried by only one haplotype,
homogeneously across subcohorts. No association
between IL18R1 haplotypes and CVD risk was observed in
any of the MORGAM cohorts, with the p-value of the glo-
bal test of association ranging from 0.138 to 0.877 in FIN-
RISK and ATBC, respectively (Additional File 2 – Tables 1
&2). In the whole MORGAM cohort, no specific haplo-
type was associated with the disease status (Figure 3).
IL18RAP gene
Again, all genotypic distributions were compatible with
HWE in all MORGAM subcohorts. All IL18RAP  SNPs
exhibited differences in allele frequencies across subco-
horts (Additional File 1). In particular, the rs4851581-G
allele was almost twice as common in Finnish popula-
tions when compared to other cohorts. None of the
IL18RAP  SNPs was consistently associated with CVD
(Table 2 – Figure 1). In the FINRISK cohort, the
rs11465702-G allele was slightly less frequent in cases
than in non-cases (0.16 vs 0.19, p = 0.048), but this asso-
ciation was not observed in others cohorts and did not
remain significant after multiple testing correction
The 6 IL18RAP  SNPs generated 7 haplotypes with fre-
quency higher than 1%. These common haplotypes were
observed in all subcohorts but with different frequencies
(Table 4). Except for the rs1420105, all rare alleles were
carried by only one haplotype, homogenously across
cohorts. No association between IL18RAP haplotypes and
CVD risk was detected in any cohort (p-values ranging
from 0.154 to 0.848 in Sweden and ATBC cohorts, respec-
tively, Additional File 2 – Tables 3 &4) nor in the whole
MORGAM sample (Figure 4).
Gene × Gene and Gene × environment analysis
Finally, we were interested in testing whether IL18R1 and
IL18RAP SNPs as well as 5 previously studied IL18 SNPs
could interact with each other or with covariates including
age, gender, smoking status and body mass index (BMI),
to modify the risk of CVD. Except for the IL18 rs360717
allele whose effects have previously been found to be
modulated by smoking [19], the search for interaction
remained unfruitful. We did not detect any interaction
between SNPs located in different genes nor between
Table 1: Description of the MORGAM cohorts
Number of individuals
Cohort Subcohorta Incident 
cases 
outside 
subcohort
All Non-cases CHDb Strokeb Smokersc Males Age at 
baselined 
(years)
Follow-up 
median/max 
(years)
FINRISK
(Finland)
700
(609/91)
476 1176 609
(51.8%)
382 (32.5%) 185 (15.7%) 285 (24.2%) 827 (70.3%) 57.0 [25–
74]
8.07/10.96
ATBC
(Finland)
849 
(718/131)
421 1270 718 (56.5%) 343 (27.0%) 209 (16.5%) 1007 
(79.3%)
1270 
(100%)
63.4 [54–
76]
7.12/8.29
Sweden 136 (128/8) 59 195 128 (65.6%) 29 (14.9%) 38 (19.5%) 37 (19.0%) 121 (62.0%) 55.8 [24–
73]
6.04/10.87
PRIME
N.Ireland
143 (135/8) 108 251 135 (53.8%) 103 (41.0%) 13 (5.2%) 66 (26.3%) 251 (100%) 54.9 [50–
60]
5.14/5.99
PRIME
France
188 (182/6) 108 296 182 (61.5%) 98 (33.1%) 16 (5.4%) 73 (24.7%) 296 (100%) 55.3 [49–
60]
5.28/7.61
Entire 2016 
(1772/244)
1172 3188 1772 
(55.6%)
955 (30.0%) 461 (14.5%) 1468 
(46.0%)
2765 
(86.7%)
59.2 [24–
76]
6.33/10.96
a Total number of individuals in the random subcohort (non-cases/cases)
b In presence of several events, only the first event was considered.
c Daily cigarette smoker at baseline
d Mean age [min - max]BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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SNPs and environmental factors. For example, Figures 5
&6 illustrate the lack of differential effects of IL18R1 and
IL18RAP haplotypes according to smoking while Figures 7
&8 display the absence of interaction with BMI.
Discussion
IL18R1 and IL18RAP genes code for two receptors of the
IL-18 cytokine that has been found associated with
atherosclerosis and its cardiovascular complications[1].
As such, they are considered as good candidates for CVD.
This motivated the present work in which IL18R1 and
IL18RAP tag SNPs were assessed for association with CVD
in different European cohorts as part of the MORGAM
Project.
Eleven SNPs, 5 in IL18R1 and 6 in IL18RAP, were studied
for association with CVD events in 5 European prospec-
tive cohorts, assembling more than 3000 subjects. Despite
some minor differences in allele frequencies across
cohorts, the haplotypic structures of these genes were
broadly homogeneous. These allele frequencies were
however comparable to those observed in HapMap Phase
III European samples populations http://www.hap
map.org or in NCBI dbSNP European database http://
www.ncbi.nlm.nih.gov/projects/SNP/. None of the single
SNPs, nor the inferred haplotypes, were found to be asso-
ciated with CVD, results that are consistent with those
reported in the AtheroGene study[9]. Because of the bio-
logical interaction between these two receptors and the IL-
18 molecule, we also investigated whether SNPs of these
3 genes (IL18R1/IL18RAP/IL18) could interact with each
other to modulate the risk of CVD. For this purpose, 5 pre-
viously studied IL18 SNPs were used [19]. No evidence for
epistasis was observed in any of the 5 cohorts (data not
Association of IL18R1 and IL18RAP SNPs with CVD risk in the whole MORGAM cohorts Figure 1
Association of IL18R1 and IL18RAP SNPs with CVD risk in the whole MORGAM cohorts. Combined ORs [95% 
confidence interval] were obtained by use of the Mantel-Haenszel method and adjusted for age, gender and smoking status.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Table 2: Allele frequenciesa of the IL18R1 and IL18RAP SNPs in the MORGAM cohorts
FINRISK
N = 1176
ATBC
N = 1270
Sweden
N = 195
PRIME/N.Ireland
N = 251
PRIME/France
N = 296
Gene SNP Non-cases
N = 609
Casesb
N = 567
Non-cases
N = 718
Cases
N = 552
Non-cases
N = 128
Cases
N = 67
Non-cases
N = 135
Cases
N = 116
Non-cases
N = 182
Cases
N = 114
IL18R1 rs1420098 (T/C) 0.37 0.38 0.39 0.41 0.43 0.41 0.42 0.42 0.41 0.37
rs1420096 (T/C) 0.46 0.47 0.46 0.47 0.52 0.43 0.50 0.48 0.55 0.53
rs11465656 (I/D) 0.04 0.04 0.04 0.04 0.03 0.02 0.04 0.06 0.05 0.03
rs3732127 (G/C) 0.21 0.18 0.17 0.17 0.14 0.22* 0.17 0.19 0.19 0.16
rs11465660 C/A) 0.10 0.10 0.12 0.12 0.13 0.13 0.11 0.07 0.07 0.07
IL18RAP rs11465670 (T/C) 0.09 0.09 0.11 0.12 0.11 0.16 0.13 0.15 0.13 0.13
rs4851581 (A/G) 0.14 0.15 0.15 0.13 0.08 0.03 0.08 0.10 0.09 0.11
rs1420106 (G/A) 0.18 0.20 0.20 0.19 0.21 0.19 0.20 0.18 0.22 0.28
rs1420105 (C/T) 0.46 0.46 0.46 0.47 0.51 0.43 0.50 0.48 0.53 0.53
rs11465673 (T/C) 0.09 0.10 0.12 0.12 0.13 0.14 0.11 0.07 0.07 0.06
rs11465702 (A/G) 0.19 0.16* 0.15 0.14 0.12 0.16 0.14 0.14 0.13 0.11
a Allele frequency of the minor allele.
b Cases: CHD and strokes were combined
*: Significant cases/non-cases comparison at p < 0.05BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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shown). We had previously observed that one IL18 SNP
interacts with smoking to modulate the risk of CVD [19].
However, no such interaction was detected with any of the
IL18R1 and IL18RAP SNPs. Results shown in this report
were obtained when CHD and stroke events were com-
bined together but treating them separately did not pro-
vide further evidence of any specific genetic effects (data
not shown).
It cannot be ruled out that the lack of association observed
in this work could be due to sample size limitations. How-
ever, power calculations showed the MORGAM project to
have a power of ~90% to detect the effect of a SNP with a
minor allele frequency (MAF) of 0.10 and associated with
an OR of at least 1.30. The same power would be achieved
for an OR of 1.20 once the MAF was higher than 0.23.
Additionally, our study is well powered to detect second-
order interactions and has, for example, a power of ~70%
Pairwise Linkage Disequilibrium between the IL18R1 and IL18RAP SNPs Figure 2
Pairwise Linkage Disequilibrium between the IL18R1 and IL18RAP SNPs. Pairwise Linkage Disequilibrium (LD) 
expressed in terms of r2 and estimated in the whole MORGAM cohort using the Haploview software (Barrett JC, Fry B, Maller 
J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263–265). The pattern of 
LD was homogeneous across the five European cohorts (data not shown).BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Association between IL18R1 haplotypes and CVD risk in the whole MORGAM cohorts Figure 3
Association between IL18R1 haplotypes and CVD risk in the whole MORGAM cohorts. Haplotypic ORs [95% con-
fidence interval] adjusted for cohorts, age, gender and smoking habits are shown by comparison to the reference TTIGC hap-
lotype. The global test of association was not significant (χ2 = 7.231 with 7 df, p = 0.405). Polymorphisms are ordered 
according to their position on the genomic sequence.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Table 3: IL18R1 gene haplotype frequencies in the MORGAM subcohorts
Polymorphisms
rs1420098 rs1420096 rs11465656 rs3732127 rs11465660 FINRISK 
N = 700
ATBC 
N = 849
Sweden 
N = 136
PRIME/
N.Ireland 
N = 143
PRIME/France 
N = 188
T T I G C 0.239 0.256 0.200 0.220 0.200
T T I G A 0.009 0.005 0.027 0.016 0.028
T T I C C 0.195 0.151 0.127 0.145 0.143
T C I G C 0.186 0.196 0.220 0.198 0.218
C T I G A 0.086 0.115 0.106 0.083 0.037
C T I C C 0.010 0.018 0.018 0.036 0.034
C C I G C 0.232 0.211 0.263 0.251 0.262
C C D G C 0.037 0.041 0.028 0.051 0.050
Association between IL18RAP haplotypes and CVD risk in the whole MORGAM cohorts Figure 4
Association between IL18RAP haplotypes and CVD risk in the whole MORGAM cohorts. Haplotypic ORs [95% 
confidence interval] adjusted for cohorts, age, gender and smoking habits are shown by comparison to the reference TAGTTA 
haplotype. The global test of association was not significant (χ2 = 1.763 with 6 df, p = 0.940). Polymorphisms are ordered 
according to their position on the genomic sequence.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Table 4: IL18RAP gene haplotype frequencies in the MORGAM subcohorts
Polymorphisms
rs11465670 rs4851581 rs1420106 rs1420105 rs11465673 rs11465702 FINRISK 
N = 700
ATBC 
N = 849
Sweden 
N = 136
PRIME/
N.Ireland 
N = 143
PRIME/
France 
N = 188
T A G C T A 0.015 0.024 0.038 0.033 0.062
T A G C T G 0.199 0.148 0.124 0.133 0.137
T A G C C A 0.095 0.119 0.135 0.111 0.071
T A G T T A 0.265 0.253 0.297 0.307 0.298
T A A T T A 0.190 0.198 0.210 0.196 0.220
T G G C T A 0.140 0.146 0.075 0.081 0.081
C A G C T A 0.094 0.109 0.120 0.137 0.127
Association between IL18R1 haplotypes and CVD risk in the whole MORGAM cohorts according to smoking status Figure 5
Association between IL18R1 haplotypes and CVD risk in the whole MORGAM cohorts according to smoking 
status. Haplotypic ORs [95% confidence interval] by comparison to the reference TTIGC haplotype were adjusted for 
cohorts, age, gender, separately in non-smokers (diamonds) and smokers (squares). The global tests of association were not 
significant (χ2 = 4.796 with 6 df, p = 0.570 in non-smokers; χ2 = 1.075 with 6 df, p = 0.983 in smokers). Polymorphisms are 
ordered according to their position on the genomic sequence.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Association between IL18RAP haplotypes and CVD risk in the whole MORGAM cohorts according to smoking status Figure 6
Association between IL18RAP haplotypes and CVD risk in the whole MORGAM cohorts according to smoking 
status. Haplotypic ORs [95% confidence interval] by comparison to the reference TAGTTA haplotype were adjusted for 
cohorts, age, gender, separately in non-smokers (diamonds) and smokers (squares). The global tests of association were not 
significant (χ2 = 2.639 with 6 df, p = 0.853 in non-smokers; χ2 = 2.028 with 6 df, p = 0.917 in smokers). Polymorphisms are 
ordered according to their position on the genomic sequence.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Association between IL18R1 haplotypes and CVD risk in the whole MORGAM cohorts according to BMI Figure 7
Association between IL18R1 haplotypes and CVD risk in the whole MORGAM cohorts according to BMI. Haplo-
typic ORs [95% confidence interval] by comparison to the reference TTIGC haplotype were adjusted for cohorts, age and gen-
der, separately in subjects below (diamonds) and above (squares) the population-specific median of BMI. The global test of 
association was neither significant in the group of individuals below (χ2 = 3.767 with 6 df, p = 0.708) nor above (χ2 = 10.28 with 
6 df, p = 0.113) the median of BMI. Polymorphisms are ordered according to their position on the genomic sequence.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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Association between IL18RAP haplotypes and CVD risk in the whole MORGAM cohorts according to BMI Figure 8
Association between IL18RAP haplotypes and CVD risk in the whole MORGAM cohorts according to BMI. Hap-
lotypic ORs [95% confidence interval] by comparison to the reference TAGTTA haplotype were adjusted for cohorts, age and 
gender, separately for subjects below (diamonds) and above (squares) the population-specific median of BMI. The global test of 
association was neither significant in the group of individuals below (χ2 = 5.379 with 6 df, p = 0.496) nor above (χ2 = 11.18 with 
6 df, p = 0.083) the median of BMI. Polymorphisms are ordered according to their position on the genomic sequence.BMC Medical Genetics 2009, 10:44 http://www.biomedcentral.com/1471-2350/10/44
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to detect a SNP × smoking interaction where a SNP with
MAF of 0.28 is associated with an OR of 1.30 in MOR-
GAM smokers only [19]
Conclusion
In conclusion, whereas IL18R1  and IL18RAP  polymor-
phisms have been found associated with diseases such as
schizophrenia, HSV1 seropositivity and atopic asthma
[16,17], our analysis of IL18R1 and IL18RAP SNPs in 5
European prospective cohorts suggests that the variability
of these genes are unlikely to contribute to modulate the
risk of CVD in European populations.
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